Myeloma News

Cancer mortality gradually declined over the past 2-plus decades, although the rate slowed between 2019 and 2022, according to results of the Annual Report to the Nation on the Status of Cancer.

More than half of patients recently diagnosed with lymphoma or myeloma had clinically significant symptoms of anxiety or depression, according to study results.

The FDA has approved two new denosumab biosimilars that are interchangeable with the reference medications Prolia and Xgeva, according to an industry press release.

The addition of subcutaneous daratumumab to triplet therapy improved outcomes for certain patients with newly diagnosed multiple myeloma, study results showed.

The vast majority of individuals who used multicancer early detection tests reported being satisfied with the test, according to data from a prospective, multicenter cohort study.

An AI-based cancer prediction system is designed to ensure a higher percentage of cancers are diagnosed at earlier, more treatable stages.

Healio is pleased to announce its partnership with CancerX, a public-private collaboration dedicated to the acceleration of innovation in cancer treatment.

Siltuximab effectively treated patients who experienced common adverse events after chimeric antigen receptor T-cell therapy, according to findings published in Blood Advances.

Healio | HemOnc Today is excited to announce the nominees for its annual Disruptive Innovators Awards in oncology and hematology.